查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1832196

抗肥胖治疗市场（按药物类别、给药途径、通路和最终用户划分）—2025-2032 年全球预测

Anti-obesity Prescription Drugs Market by Drug Class, Administration Route, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，抗肥胖治疗市场将成长至 127.7 亿美元，复合年增长率为 8.35%。

主要市场统计数据
基准年2024年 67.1亿美元
预计2025年 72.8亿美元
预测年份：2032年 127.7亿美元
复合年增长率（%） 8.35%

简洁的抗肥胖疗法方向以及不断变化的临床、商业性和管理动态，改变了相关人员的决策

在科学突破、新型给药方式以及支付者和政策审查力度加大的推动下，处方抗肥胖药物的治疗和商业性格局正在发生重大变革时期。临床医师越来越多地将新型荷尔蒙药物纳入治疗方案，与仍在服务特定患者族群的传统药物并存。同时，器械创新和新型口服剂型正在改变治疗药物的给药和监测方式，为依从性干预和病人参与创造了新的接触点。

在此背景下，从生物技术创新者到医院系统的相关人员正在重新思考其营运假设。曾经线性的供应链如今面临新的采购要求和产能压力，竞争格局的特征是产品快速差异化和策略联盟的形成。临床疗效、耐受性和便利性之间不断变化的相互作用正在重塑处方行为和医疗服务模式，这促使临床开发、监管事务、商业团队和分销合作伙伴之间开展跨职能协作。

科学突破、交付创新和整合数位支援系统如何重新定义抗肥胖药物治疗的治疗策略和护理途径

近年来，科学进步已将药物治疗肥胖的模式从对症干预转变为基于机制的生理学方法，这些方法能够影响食慾调节、饱腹感信号传导和能量平衡。基于肠促胰岛素的疗法的出现及其临床检验，加速了人们对多药组合方案和联合用药策略的兴趣，促使研发人员探索现有的胜肽类药物以及靶向互补通路的下一代分子。因此，临床试验设计、终点选择和长期安全性监测均已发展，以反映对持续体重管理和心臟代谢益处的期望。

同时，药物输送和患者体验领域正在发生重要的创新。长效注射剂、患者友善型自动注射器和预填充註射笔以及改进的口服製剂重塑了关于依从性的讨论，并带来了新的诊疗点。用于依从性监测、远端滴定和行为支持的数位化工具越来越多地与药物治疗相结合，透过改善疗效提升了治疗价值。最后，现实世界的有效性、卫生经济学证据和病患分层是市场准入和报销讨论的核心，这些因素共同影响着处方集的部署和临床应用轨迹。

评估近期美国关税行动对全球供应链、製造决策以及处方笺抗减肥药取得途径的连锁营运影响

主要经济体的政策调整和关税措施有可能显着重塑全球复杂疗法的供应链和成本结构。美国2025年的关税环境为处方笺抗肥胖药物的筹资策略、製造外包关係和库存规划带来了新的考量。企业正在重新评估供应商集中度风险，并探索替代性生产布局，以降低贸易政策波动带来的风险。

这些调整会影响製造前置作业时间、品质保证监管和总到岸成本，进而影响筹资策略以及进入某些管道的商业性合理性。为此，许多相关人员正在寻求双重采购、关键流程近岸外包，并与物流供应商重新协商业务条款。重要的是，法规合规性和供应链可追溯性是这些努力的核心，因为企业需要在成本控制与确保患者在整个分销网络中获得不间断治疗的需求之间取得平衡。

深入细分主导的分析，将药物类别、剂型、分销渠道和最终用户环境联繫起来，为有针对性的开发和商业化策略提供信息

了解患者群体和产品模式对于制定抗肥胖产品组合的临床开发、商业化和分销策略至关重要。药物类别包括Amylin类似物（例如Pramlintide） 、GLP-1促效剂（例如度拉Dulaglutide肽、艾塞那肽、Exenatide和Semaglutide）、脂肪酶Liraglutide（例如奥利司他）以及血清素受体调变器剂（例如氯卡色林）。另一方面，口服胶囊和片剂为不愿注射的患者提供了便利，并有机会在基层医疗中推广使用。

分销管道和终端用户环境进一步加深了机会和风险。传统的线下管道对于临床监测、病患教育和低温运输支援仍然至关重要，而线上药局和远端医疗配药则扩大了通路覆盖面并提升了便利性，尤其对于慢性病管理而言。终端使用者涵盖门诊护理中心、医院、居家照护机构和专科诊所。专科诊所、内分泌诊所、全科医生和减重诊所都需要量身定制的支援、教育材料和临床通讯协定。因此，商业化策略必须细緻入微，将产品属性与用药偏好、通路动态以及每种处方类型和护理环境的独特需求相结合。

区域比较观点，重点关注美洲、中东和非洲以及亚太地区的监管预期、付款人动态和分销细微差别

区域动态以独特的方式塑造着监管路径、付款人互动以及更广泛的临床实践生态系统。在美洲，监管机构和付款人严格评估长期安全性和成本效益，而医疗服务提供者网路正在迅速采用整合药物治疗和行为多模态护理模式。该地区的商业基础设施既支援专科诊所服务，也支持利用远端医疗医疗扩大分销，并促进了利用数位化依从性工具的灵活上市策略。

欧洲、中东和非洲呈现出差异化的监管和报销格局，需要根据地区制定针对性的证据来产生和参与方式。许多国家高度重视严格的卫生经济评估和比较有效性数据，这些数据会影响价格谈判和处方取得。与当地经销商和专科诊所合作，对于应对该地区分散的配送管道通常至关重要。亚太市场成熟度参差不齐，一些国家正在推动最先进治疗的快速普及，并藉助一体化的医院体系和强大的製造能力；而另一些国家则优先考虑成本控制和国内生产。因此，供应链的韧性、监管协调工作以及适应当地文化的患者援助计划是全部区域的关键考虑因素。

策略公司概况和联盟架构揭示了整合开发、设备工程和数位伙伴关係关係如何塑造竞争差异化和营运弹性

竞争格局涵盖传统製药商、生技药品专家、新兴生物技术创新者、设备製造商、受託製造厂商和数位健康供应商。拥有生技药品开发、注射设备工程和低温运输物流综合能力的公司在将肽基疗法推向市场方面拥有独特的营运优势。同时，敏捷的生物技术公司正在开发新颖的作用机制和新配方，通常利用策略伙伴关係和授权协议来获得生产规模和商业基础设施。

供应链和契约製造合作伙伴在产品可用性和成本效益方面发挥着日益关键的作用。提供以患者为中心的自动注射器和使用者友好型注射笔的设备製造商正在提高依从性并支持医疗保健专业人员 (HCP) 的采用。提供行为指导、远端滴定和依从性分析的数位疗法供应商正成为药物治疗的重要辅助手段，使他们能够向付款人和提供者展示价值。在整个製药行业，从共同开发契约到分销合作等各种合作模式对于降低上市风险和缩短时间患者获得药物至关重要。

製药、製造和商业团队的行动导向策略重点，以协调证据产生、供应弹性和付款人伙伴关係，实现永续获取

为了保持竞争优势，产业领导者应优先制定整合策略，将临床定位、生产韧性和付款人参与度协调一致。首先，投资于产生超越对照试验的可靠安全性和真实世界证据，对于支持覆盖范围讨论和证明患者的长期获益至关重要。在产生证据的同时，扩展设备和製剂选择可以满足不同的给药偏好和依从性需求，从而扩大可覆盖的患者群体。

在营运方面，透过地理分布的製造、战略契约製造伙伴关係以及增强的原材料可追溯性来多元化供应链布局，可以减少政策衝击和产能限制的风险。商业团队应部署针对特定管道的方法，将诊所启动通讯协定与远端医疗追踪和数位化依从性支援相结合，以优化医疗服务的连续性。最后，与付款人和医疗系统进行选择性合作，制定基于结果的风险共担协议，可以促进医疗服务的可及性，同时围绕可衡量的临床结果和成本补偿调整奖励。

对严格的多方法调查方法的透明描述，该方法结合了临床文献综述、专家访谈、製造评估和数据三角测量

本研究综合运用多种方法，将同侪审查的临床文献、监理备案文件、指导文件和公共声明的结构化评审与有针对性的一手资料研究结合。与内分泌科和基层医疗的临床医生、监管专家、供应链高管、付款方和患者权益代表进行了专家咨询，以检验关键趋势和营运影响。製造和物流评估包括与製造外包製造商、设备供应商和低温运输供应商进行技术简报，以评估产能考量和缓解策略。

本研究采用资料三角测量和交叉检验技术，将质性洞察与公开的临床和监管资讯进行比对。研究应用细分映射，将药物类别属性与给药方式、管道动态和最终用户需求进行配对。品质保证方案包括专家同侪审查、跨地区评估一致性检查以及与权威监管文件进行事实检验。所有主要访谈和个人化意见均遵循伦理考量和保密措施。

关于临床创新、供应弹性和付款人参与如何融合以决定抗减肥药的长期可及性和策略成功的综合、封闭的观点

处方抗减肥药的发展轨迹由科学创新、新的交付模式以及不断变化的政策和付款人期望决定，这些因素共同创造了机会，也带来了复杂性。利用生理机制的治疗方法正在促使人们重新思考长期管理策略，而剂量和数位化支持的进步则拓宽了护理环境和依从性工具的频谱。同时，监管审查和采购动态迫使企业提供更有力的现实世界证据，并设计能够抵御地缘政治和贸易政策动盪的弹性供应链。

因此，决策者必须采取整合的策略，将临床证据、生产策略和商业性执行结合起来。这样做将使公司能够更好地将产品属性与患者需求相结合，确保跨渠道和跨地域的可靠获取，并向付款人和医疗保健提供者展示其价值。未来几年，那些将临床可信度与营运敏捷性以及以伙伴关係主导的商业化相结合，从而确保患者永续获得有效抗肥胖药物的利益相关人员将获得丰厚回报。

目录

第一章 引言

第二章分析方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 肥胖併发症导致 GLP-1 受体促效剂迅速普及
  • 减少心血管事件的真实数据推动了抗肥胖药物的广泛采用
  • 改良的配方允许口服注射减肥药
  • 病人依从性挑战推动体重管理的数位健康整合
  • 保险公司根据长期医疗保健成本节省的证据扩大保险范围
  • 针对GIP和GLP-1双重治疗途径的竞争性药物管线的出现

第六章：美国关税的累积影响（2025年）

第七章：人工智慧（AI）的累积影响（2025年）

第 8 章：按药物类别分類的抗肥胖药物市场

  • Amylin 类似物
    • 普兰林胜肽
  • GLP-1促效剂
    • Dulaglutide
    • Exenatide
    • Liraglutide
    • Semaglutide
  • 脂肪酶抑制剂
    • 奥利司他
  • 血清素受体调变器
    • 氯卡色林

9. 抗肥胖药物市场（依给药途径）

  • 注射
    • 自动注射器
    • 预填充笔
    • 管瓶和注射器
  • 口服
    • 胶囊
    • 药片

第 10 章。按分销管道分類的抗肥胖药物市场

  • 离线
  • 在线的

第 11 章。 抗肥胖治疗市场（按最终用户）

  • 门诊治疗中心
  • 居家医疗
  • 医院
  • 专科诊所
    • 内分泌科诊所
    • 综合诊所
    • 减重诊所

第 12 章：按地区分類的减重药物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 抗肥胖药物市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 14 章。各国抗肥胖药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 市占率分析（2024年）
  • FPNV定位矩阵（2024年）
  • 竞争分析
    • Novo Nordisk A/S
    • Eli Lilly and Company
    • Pfizer Inc.
    • AstraZeneca PLC
    • Sanofi SA
    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Roche Holding AG
    • Boehringer Ingelheim International GmbH
Product Code: MRR-4358BACA7FD1

The Anti-obesity Prescription Drugs Market is projected to grow by USD 12.77 billion at a CAGR of 8.35% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 6.71 billion
Estimated Year [2025] USD 7.28 billion
Forecast Year [2032] USD 12.77 billion
CAGR (%) 8.35%

A concise orientation to the evolving clinical, commercial, and operational dynamics transforming prescription anti-obesity therapeutics and stakeholder decision-making

The therapeutic and commercial landscape for prescription anti-obesity drugs has entered a period of pronounced transformation driven by scientific breakthroughs, novel delivery formats, and intensified payer and policy scrutiny. Clinicians are increasingly integrating newer hormone-based agents into care pathways alongside legacy medications that continue to serve specific patient segments. Meanwhile, device innovations and novel oral formulations are changing how therapies are administered and monitored, creating fresh touchpoints for adherence interventions and patient engagement efforts.

Against this backdrop, stakeholders from biotech innovators to hospital systems must re-evaluate operational assumptions. Supply chains that were once linear are now subject to new sourcing requirements and capacity pressures, and the competitive environment is characterized by rapid product differentiation and strategic collaborations. The evolving interplay of clinical efficacy, tolerability profiles, and convenience is reshaping prescribing behavior and care delivery models, requiring cross-functional alignment between clinical development, regulatory affairs, commercial teams, and distribution partners.

How scientific breakthroughs, delivery innovations, and integrated digital support systems are collectively redefining therapeutic strategies and care pathways in anti-obesity pharmacotherapy

Recent scientific advances have shifted the paradigm of pharmacologic obesity management from symptomatic interventions to mechanistic, physiology-based approaches that impact appetite regulation, satiety signaling, and energy homeostasis. The emergence and clinical validation of incretin-based therapies have accelerated interest in multimodal regimens and combination strategies, prompting developers to explore both established peptide classes and next-generation molecules targeting complementary pathways. As a result, clinical trial design, endpoint selection, and long-term safety monitoring have all evolved to reflect expectations for sustained weight management and cardiometabolic benefit.

Concurrently, the realm of drug delivery and patient experience has seen meaningful innovation. Long-acting injectables, patient-friendly autoinjectors and prefilled pens, and improved oral formulations have reframed adherence conversations and enabled new points of care. Digital tools for adherence monitoring, remote titration, and behavioral support are increasingly integrated with pharmacotherapy, reinforcing therapeutic value through improved outcomes. Finally, market access and reimbursement dialogues now center on real-world effectiveness, health-economic evidence, and patient stratification, which together influence formulary placement and clinical adoption trajectories.

Assessment of the cascading operational consequences of recent United States tariff measures on global supply chains, manufacturing decisions, and access pathways for prescription anti-obesity therapeutics

Policy adjustments and tariff actions in major economies can materially reconfigure global supply chains and cost structures for complex therapeutics, particularly when active pharmaceutical ingredients, biologics manufacturing inputs, and finished-dose forms cross multiple borders during production. The 2025 tariff environment in the United States has introduced new considerations for sourcing strategies, contract manufacturing relationships, and inventory planning for prescription anti-obesity products. Companies are reassessing supplier concentration risks and exploring alternative manufacturing footprints to mitigate exposure to trade-policy volatility.

This recalibration has implications for manufacturing lead times, quality assurance oversight, and total landed costs, which in turn affect procurement strategies and the commercial calculus for entry into specific channels. In response, many stakeholders are pursuing dual-sourcing arrangements, nearshoring of critical processes, and renegotiation of commercial terms with logistics providers. Importantly, regulatory compliance and supply-chain traceability have become central to these efforts, as firms balance cost containment with the necessity of maintaining uninterrupted patient access to therapies across distribution networks.

Deep segmentation-driven analysis linking drug classes, administration formats, distribution channels, and end-user environments to inform precise development and commercialization tactics

Understanding patient segments and product modalities is essential to tailoring clinical development, commercialization, and distribution strategies across the anti-obesity portfolio. Drug classes span amylin analogs such as pramlintide, a range of GLP-1 agonists including dulaglutide, exenatide, liraglutide, and semaglutide, lipase inhibitors exemplified by orlistat, and serotonin receptor modulators like lorcaserin; each class presents distinct efficacy, safety, and tolerability profiles that inform positioning and prescriber choice. Moreover, formulation and administration route drive differential adoption patterns: injectables delivered via autoinjectors, prefilled pens, and traditional vial-and-syringe formats attract patients and providers seeking longer-acting or titratable therapies, while oral capsules and tablets offer convenience for those averse to injections and opportunities for primary care adoption.

Distribution channels and end-user settings further stratify opportunity and risk. Traditional offline channels remain important for clinical oversight, patient education, and cold-chain handling, while online pharmacies and telehealth-enabled dispensing expand access and convenience, particularly for chronic management. End users range from ambulatory care centers and hospitals to home-care settings and specialty clinics; within specialty clinics, endocrinology practices, general practice clinics, and weight-loss clinics each demand tailored support, educational materials, and clinical protocols. Therefore, commercialization strategies must be nuanced, aligning product attributes with administration preferences, channel dynamics, and the specific needs of prescriber types and care settings.

Comparative regional perspectives highlighting regulatory expectations, payer dynamics, and distribution nuances across the Americas; Europe, Middle East & Africa; and Asia-Pacific territories

Regional dynamics shape regulatory pathways, payor interactions, and the broader ecosystem of clinical practice in distinctive ways. In the Americas, regulatory agencies and payers are closely evaluating long-term safety and cost effectiveness, while provider networks are rapidly adopting multimodal care models that integrate pharmacotherapy with behavioral interventions. The commercial infrastructure in this region supports both specialty clinic delivery and expanding telehealth-enabled distribution, encouraging flexible launch strategies that leverage digital adherence tools.

Europe, the Middle East & Africa present heterogeneous regulatory and reimbursement landscapes that require localized evidence generation and engagement approaches. Many countries emphasize rigorous health-economic assessments and comparative effectiveness data, which influences pricing negotiations and formulary access. In this region, partnerships with regional distributors and specialized clinics are often essential to navigate fragmented delivery channels. Asia-Pacific markets exhibit diverse maturity levels; some countries are advancing rapid uptake of cutting-edge therapies supported by integrated hospital systems and strong manufacturing capabilities, while others are prioritizing cost containment and domestic production. Supply-chain resilience, regulatory harmonization efforts, and culturally adapted patient-support programs are therefore critical considerations across these geographies.

Strategic company profiles and alliance architectures that reveal how integrated development, device engineering, and digital partnerships are shaping competitive differentiation and operational resilience

The competitive landscape encompasses legacy pharmaceutical manufacturers, biologics specialists, emerging biotech innovators, device makers, contract manufacturing organizations, and digital health vendors. Firms with integrated capabilities across biologics development, device engineering for injectables, and cold-chain logistics possess distinct operational advantages when bringing peptide-based therapies to market. Simultaneously, agile biotech companies are advancing novel mechanisms of action and new formulations, often leveraging strategic partnerships or licensing deals to access manufacturing scale and commercial infrastructure.

Supply-chain and contract manufacturing partners are increasingly visible as pivotal contributors to product availability and cost efficiency. Device manufacturers that can deliver patient-centered autoinjectors and user-friendly pens enhance adherence and support provider uptake. Digital therapeutics vendors offering behavioral coaching, remote titration, and adherence analytics are becoming important adjuncts to pharmacotherapy, enabling value demonstrations to payers and providers. Across the sector, collaborative models-ranging from co-development agreements to distribution partnerships-are central to de-risking launches and accelerating time to patient access.

Action-oriented strategic priorities for pharmaceutical, manufacturing, and commercial teams to align evidence generation, supply resilience, and payer partnerships for sustained access

Industry leaders should prioritize integrated strategies that align clinical positioning, manufacturing resilience, and payer engagement to sustain competitive advantage. First, investing in robust safety and real-world evidence generation that extends beyond controlled trials will be essential to support coverage conversations and demonstrate long-term patient benefit. Parallel to evidence generation, expanding device and formulation options can broaden the addressable patient base by meeting diverse administration preferences and adherence needs.

Operationally, diversifying supply-chain footprints via geographically distributed manufacturing, strategic contract manufacturing partnerships, and enhanced raw-material traceability will reduce exposure to policy shocks and capacity constraints. Commercial teams should deploy channel-specific approaches that integrate in-clinic initiation protocols with telehealth follow-up and digital adherence supports to optimize continuity of care. Finally, pursuing selective collaborations with payers and health systems to develop outcomes-based contracts or risk-sharing agreements can facilitate access while aligning incentives around measurable clinical outcomes and cost offsets.

Transparent description of the rigorous multi-method research approach combining clinical literature review, expert interviews, manufacturing assessments, and data triangulation

This research synthesizes a multi-method approach combining a structured review of peer-reviewed clinical literature, regulatory filings, guidance documents, and public policy statements with targeted primary research. Expert consultations were conducted with clinicians across endocrinology and primary care, regulatory specialists, supply-chain executives, payers, and patient advocacy representatives to validate key trends and operational implications. Manufacturing and logistics assessments drew on technical briefings with contract manufacturers, device suppliers, and cold-chain providers to assess capacity considerations and mitigation strategies.

Data triangulation and cross-validation techniques were used to reconcile qualitative insights with publicly available clinical and regulatory information. The study applied segmentation mapping to align drug-class attributes with delivery modalities, channel dynamics, and end-user needs. Quality assurance protocols included peer review by subject-matter experts, consistency checks across regional assessments, and verification of factual statements against authoritative regulatory documents. Ethical considerations and confidentiality safeguards were maintained for all primary interviews and proprietary inputs.

A synthesized closing perspective on how clinical innovation, supply resilience, and payer engagement converge to determine long-term access and strategic success in anti-obesity therapeutics

The trajectory of prescription anti-obesity therapeutics is defined by scientific innovation, new delivery models, and shifting policy and payer expectations that together create both opportunity and complexity. Emerging therapies that leverage physiologic mechanisms have catalyzed rethinking of long-term management strategies, while advances in administration and digital support expand the spectrum of care settings and adherence tools. At the same time, regulatory scrutiny and procurement dynamics are compelling firms to produce stronger real-world evidence and to design resilient supply chains that can withstand geopolitical and trade-policy disruptions.

Decision-makers must therefore adopt integrated playbooks that bring clinical evidence, manufacturing strategy, and commercial execution into alignment. By doing so, organizations can better match product attributes to patient needs, secure reliable access across channels and geographies, and demonstrate value to payers and providers. The coming years will reward stakeholders who combine clinical credibility with operational agility and partnership-driven commercialization, enabling sustainable patient access to effective anti-obesity pharmacotherapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of GLP-1 receptor agonists driven by obesity comorbidity outcomes
  • 5.2. Real-world cardiovascular event reduction data boosting anti-obesity drug uptake
  • 5.3. Formulation improvements enabling oral administration of injectable obesity therapies
  • 5.4. Patient adherence challenges prompting digital health integration for weight management
  • 5.5. Payers expanding coverage policies in response to long-term health cost savings evidence
  • 5.6. Emerging competitive pipeline drugs targeting dual GIP and GLP-1 therapeutic pathways

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-obesity Prescription Drugs Market, by Drug Class

  • 8.1. Amylin Analogs
    • 8.1.1. Pramlintide
  • 8.2. GLP-1 Agonists
    • 8.2.1. Dulaglutide
    • 8.2.2. Exenatide
    • 8.2.3. Liraglutide
    • 8.2.4. Semaglutide
  • 8.3. Lipase Inhibitors
    • 8.3.1. Orlistat
  • 8.4. Serotonin Receptor Modulators
    • 8.4.1. Locaserin

9. Anti-obesity Prescription Drugs Market, by Administration Route

  • 9.1. Injectables
    • 9.1.1. Auto-Injectors
    • 9.1.2. Prefilled Pens
    • 9.1.3. Vials And Syringes
  • 9.2. Orals
    • 9.2.1. Capsules
    • 9.2.2. Tablets

10. Anti-obesity Prescription Drugs Market, by Distribution Channel

  • 10.1. Offline
  • 10.2. Online

11. Anti-obesity Prescription Drugs Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Home Care Settings
  • 11.3. Hospitals
  • 11.4. Specialty Clinics
    • 11.4.1. Endocrinology Clinics
    • 11.4.2. General Practice Clinics
    • 11.4.3. Weight Loss Clinics

12. Anti-obesity Prescription Drugs Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Anti-obesity Prescription Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Anti-obesity Prescription Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Novo Nordisk A/S
    • 15.3.2. Eli Lilly and Company
    • 15.3.3. Pfizer Inc.
    • 15.3.4. AstraZeneca PLC
    • 15.3.5. Sanofi S.A.
    • 15.3.6. GlaxoSmithKline plc
    • 15.3.7. Johnson & Johnson
    • 15.3.8. Merck & Co., Inc.
    • 15.3.9. Roche Holding AG
    • 15.3.10. Boehringer Ingelheim International GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ANTI-OBESITY PRESCRIPTION DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PRAMLINTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PRAMLINTIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PRAMLINTIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PRAMLINTIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PRAMLINTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PRAMLINTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DULAGLUTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DULAGLUTIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DULAGLUTIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DULAGLUTIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DULAGLUTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DULAGLUTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY EXENATIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY EXENATIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY EXENATIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY EXENATIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY EXENATIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY EXENATIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LOCASERIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LOCASERIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LOCASERIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LOCASERIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LOCASERIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LOCASERIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AUTO-INJECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AUTO-INJECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AUTO-INJECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AUTO-INJECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AUTO-INJECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AUTO-INJECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PREFILLED PENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PREFILLED PENS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PREFILLED PENS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PREFILLED PENS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PREFILLED PENS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PREFILLED PENS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY VIALS AND SYRINGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY VIALS AND SYRINGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY VIALS AND SYRINGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY VIALS AND SYRINGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY VIALS AND SYRINGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY VIALS AND SYRINGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ENDOCRINOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ENDOCRINOLOGY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ENDOCRINOLOGY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ENDOCRINOLOGY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ENDOCRINOLOGY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ENDOCRINOLOGY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY WEIGHT LOSS CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY WEIGHT LOSS CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY WEIGHT LOSS CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY WEIGHT LOSS CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY WEIGHT LOSS CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY WEIGHT LOSS CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 287. EUR